利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.041 秒)

    Quantitative Assays for Ras p21 in Body Fluids
    2.
    发明申请
    Quantitative Assays for Ras p21 in Body Fluids 审中-公开
    体液中Ras p21的定量测定

    公开(公告)号：US20100167324A1

    公开(公告)日：2010-07-01

    申请号：US11917471

    申请日：2006-06-23

    申请人： Walter P. Carney ,  Peter J. Hamer ,  Karen Pierce ,  Sheryl Brown-Shimer

    发明人： Walter P. Carney ,  Peter J. Hamer ,  Karen Pierce ,  Sheryl Brown-Shimer

    IPC分类号： G01N33/53 ,  C12Q1/34

    CPC分类号： G01N33/574 ,  G01N33/5748 ,  G01N2333/82 ,  G01N2800/44

    摘要： The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.

    摘要翻译： 本发明涉及体液中总ras p21的检测和定量，特别是受试者体液中总ras p21水平的连续变化。 此外，本发明涉及与一种或多种其它蛋白质，例如癌蛋白，血管生成因子，肿瘤标志物，抑制剂，生长因子受体，转移蛋白和肿瘤抑制因子结合检测和定量总ras p21。 所公开的方法是用于肿瘤前/肿瘤疾病的诊断/预后，并且可用于为患有肿瘤前/肿瘤疾病的患者选择治疗。 所公开的方法对于监测患者的肿瘤前/肿瘤疾病的状态和/或监测患者如何应对抗癌疗法是进一步有用的。

    Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples
    3.
    发明授权
    Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples 有权
    基于表皮生长因子受体（EGFR）细胞外结构域（ECD）分析物，单独或与其他分析物组合在体液样品中的水平的癌症患者监测的测定

    公开(公告)号：US07473534B2

    公开(公告)日：2009-01-06

    申请号：US10375371

    申请日：2003-02-27

    申请人： Walter P. Carney ,  Peter J. Hamer ,  Allan Lipton ,  Kim Leitzel ,  Suhail M. Ali

    发明人： Walter P. Carney ,  Peter J. Hamer ,  Allan Lipton ,  Kim Leitzel ,  Suhail M. Ali

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57488 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57449 ,  G01N2333/485 ,  G01N2333/71 ,  G01N2800/52

    摘要： The present invention describes clinically and medically important methods of monitoring the outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2/neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2/neu relative to control levels indicates poor outcome and short time to progression.

    摘要翻译： 本发明描述了临床和医学上重要的监测患有疾病或正在接受他或她的疾病的治疗或治疗的癌症患者的结果的方法。 更具体地，本发明提供了通过测量取自癌症患者的样品中表皮生长因子受体（EGFR）的细胞外结构域（ECD）的水平来监测癌症患者的疾病进展或癌症治疗有效性的方法 ，优选在治疗前，治疗开始时和治疗期间的不同时间间隔，其中与正常对照个体中EGFR的ECD水平相比，癌症患者中EGFR的ECD水平降低 作为癌症进展或进展的指标和/或患者缺乏治疗有效性。 作为确定疾病结果和存活的另一方面，本发明进一步提供了在患者样品中组合评价EGFR和HER-2 / neu水平。 与控制水平相比，伴随HER-2 / neu水平升高或升高的EGFR水平降低的发现表明结果差，进展时间短。

    ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES
    4.
    发明申请
    ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES 审中-公开
    基于体液活化剂体系中分子激活因子分析水平的癌症患者监测的测定

    公开(公告)号：US20120220524A1

    公开(公告)日：2012-08-30

    申请号：US13407641

    申请日：2012-02-28

    申请人： Walter P. Carney ,  Peter J. Hamer

    发明人： Walter P. Carney ,  Peter J. Hamer

    IPC分类号： A61K38/22 ,  A61P35/00

    CPC分类号： G01N33/57484 ,  G01N33/86 ,  G01N2333/8132 ,  G01N2333/9723 ,  G01N2800/52 ,  Y10T436/25

    摘要： The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.

    摘要翻译： 本发明描述了随时间的检查，筛选和监测正在接受治疗或治疗的癌症患者的结果的方法。 更具体地，本发明提供了通过测量纤溶酶原激活物（uPA）系统的一种或多种分析物的水平，即uPA，PAI-1，在癌症患者中监测疾病进展或癌症治疗的有效性的方法， 1和来自癌症患者的样品中的uPA：PAI-1的复合物，优选在治疗前，治疗开始时和治疗期间的各个时间间隔。 正常对照个体中相应的PA系统分析物中的一种或多种水平与癌症患者中的一种或多种PA系统分析物水平的增加或升高相关，作为癌症进展或进展的指标。

    Assays for Cancer Patient Monitoring Based on Levels of Analyte Components of the Plasminogen Activator System in Body Fluid Samples
    5.
    发明申请
    Assays for Cancer Patient Monitoring Based on Levels of Analyte Components of the Plasminogen Activator System in Body Fluid Samples 审中-公开
    基于体液样品中纤溶酶原激活物系统分析物成分水平的癌症患者监测分析

    公开(公告)号：US20090286268A1

    公开(公告)日：2009-11-19

    申请号：US12507737

    申请日：2009-07-22

    申请人： Walter P. Carney ,  Peter J. Hamer

    发明人： Walter P. Carney ,  Peter J. Hamer

    IPC分类号： G01N33/53

    CPC分类号： G01N33/57484 ,  G01N33/86 ,  G01N2333/8132 ,  G01N2333/9723 ,  G01N2800/52 ,  Y10T436/25

    摘要： The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.

    摘要翻译： 本发明描述临床和医学上重要的随时间的检查，筛选和监测正在接受治疗或治疗他或她的疾病的癌症患者的结果的重要方法。 更具体地，本发明提供了通过测量纤溶酶原激活物（uPA）系统的一种或多种分析物的水平，即uPA，PAI-1，在癌症患者中监测疾病进展或癌症治疗的有效性的方法， 1和来自癌症患者的样品中的uPA：PAI-1的复合物，优选在治疗前，治疗开始时和治疗期间的各个时间间隔。 作为执行该方法的结果，癌症患者中的一种或多种PA系统分析物的水平的增加或升高与正常对照个体中相应的PA系统分析物中的一个或多个水平相比作为 癌症进展或进展和/或患者缺乏治疗有效性。

    QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS
    7.
    发明申请
    QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS 审中-公开
    身体液体中P21的定量测定

    公开(公告)号：US20140093890A1

    公开(公告)日：2014-04-03

    申请号：US14051589

    申请日：2013-10-11

    申请人： Walter P. Carney ,  Peter J. Hamer ,  Karen Pierce ,  Sheryl Brown-Shimer

    发明人： Walter P. Carney ,  Peter J. Hamer ,  Karen Pierce ,  Sheryl Brown-Shimer

    IPC分类号： G01N33/574

    CPC分类号： G01N33/574 ,  G01N33/5748 ,  G01N2333/82 ,  G01N2800/44

    摘要： The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.

    摘要翻译： 本发明涉及体液中总ras p21的检测和定量，特别是受试者体液中总ras p21水平的连续变化。 此外，本发明涉及与一种或多种其它蛋白质如癌蛋白，血管生成因子，肿瘤标志物，抑制剂，生长因子受体，转移蛋白和肿瘤抑制剂的结合来检测和定量总ras p21。 所公开的方法是用于肿瘤前/肿瘤疾病的诊断/预后，并且可用于为患有肿瘤前/肿瘤疾病的患者选择治疗。 所公开的方法对于监测患者的肿瘤前/肿瘤疾病的状态和/或监测患者如何应对抗癌疗法是进一步有用的。

    Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
    8.
    发明授权
    Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples 失效
    基于体液样品中纤溶酶原激活物系统的分析物成分水平进行癌症患者监测的测定

    公开(公告)号：US07732159B2

    公开(公告)日：2010-06-08

    申请号：US11965323

    申请日：2007-12-27

    申请人： Walter P. Carney ,  Peter J. Hamer

    发明人： Walter P. Carney ,  Peter J. Hamer

    IPC分类号： C12Q1/00 ,  C12Q33/00 ,  C12Q33/48 ,  A01N37/18 ,  A01N61/00 ,  A61K31/00 ,  A61K38/00 ,  A61K38/28 ,  A61K49/00 ,  A61K51/00 ,  A61M36/14

    CPC分类号： G01N33/57484 ,  G01N33/86 ,  G01N2333/8132 ,  G01N2333/9723 ,  G01N2800/52 ,  Y10T436/25

    摘要： The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.

    摘要翻译： 本发明描述临床和医学上重要的随时间的检查，筛选和监测正在接受治疗或治疗他或她的疾病的癌症患者的结果的重要方法。 更具体地，本发明提供了通过测量纤溶酶原激活物（uPA）系统的一种或多种分析物的水平，即uPA，PAI-1，在癌症患者中监测疾病进展或癌症治疗的有效性的方法， 1和来自癌症患者的样品中的uPA：PAI-1的复合物，优选在治疗前，治疗开始时和治疗期间的各个时间间隔。 作为执行该方法的结果，癌症患者中的一种或多种PA系统分析物的水平的增加或升高与正常对照个体中相应的PA系统分析物中的一个或多个水平相比作为 癌症进展或进展和/或患者缺乏治疗有效性。